---
title: "CRISPR Therapeutics AG (CRSP.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CRSP.US.md"
symbol: "CRSP.US"
name: "CRISPR Therapeutics AG"
industry: "Biotechnology"
datetime: "2026-05-20T22:43:11.306Z"
locales:
  - [en](https://longbridge.com/en/quote/CRSP.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CRSP.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CRSP.US.md)
---

# CRISPR Therapeutics AG (CRSP.US)

## Company Overview

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.crisprtx.com](https://www.crisprtx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: D (0.75)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 211 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -89.11% |  |
| Net Profit YoY | -47.42% |  |
| P/B Ratio | 2.53 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4589998011.28 |  |
| Revenue | 4103000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -31.21% | E |
| Profit Margin | -13856.54% | E |
| Gross Margin | -7754.80% | E |
| Revenue YoY | -89.11% | E |
| Net Profit YoY | -47.42% | D |
| Total Assets YoY | 25.84% | A |
| Net Assets YoY | -0.80% | D |
| Cash Flow Margin | 70.35% | C |
| OCF YoY | -89.11% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 33.43% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - CRISPR Therapeutics AG",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-89.11%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-47.42%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.53",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4589998011.28",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4103000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-31.21%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-13856.54%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-7754.80%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-89.11%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-47.42%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "25.84%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.80%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "70.35%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-89.11%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "33.43%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -8.07 | 423/386 | - | - | - |
| PB | 2.53 | 228/386 | 3.01 | 2.76 | 2.45 |
| PS (TTM) | 1118.69 | 294/386 | 1288.88 | 140.60 | 127.05 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **26**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 12 | 46% |
| Overweight | 4 | 15% |
| Hold | 9 | 35% |
| Sell | 1 | 4% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 48.55 |
| Highest Target | 291.00 |
| Lowest Target | 33.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CRSP.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CRSP.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CRSP.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CRSP.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**